ERBB2 and ovarian carcinoma: Olaparib is a potent poly (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of patients with ovarian cancer and patients with breast cancer (BRCA)–mutated human epidermal growth factor receptor-2 (HER2) negative metastatic breast cancer [1, 2].